Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab

SIMPLE SUMMARY: Immunotherapy is now the standard front-line therapy for patients with advanced hepatocellular carcinoma. However, there remains a substantial proportion of patient who do not respond to this treatment, and few predictive and prognostic biomarkers exist that can identify patients mos...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Yue Linda, Fulgenzi, Claudia Angela Maria, D’Alessio, Antonio, Cheon, Jaekyung, Nishida, Naoshi, Saeed, Anwaar, Wietharn, Brooke, Cammarota, Antonella, Pressiani, Tiziana, Personeni, Nicola, Pinter, Matthias, Scheiner, Bernhard, Balcar, Lorenz, Huang, Yi-Hsiang, Phen, Samuel, Naqash, Abdul Rafeh, Vivaldi, Caterina, Salani, Francesca, Masi, Gianluca, Bettinger, Dominik, Vogel, Arndt, Schönlein, Martin, von Felden, Johann, Schulze, Kornelius, Wege, Henning, Galle, Peter R., Kudo, Masatoshi, Rimassa, Lorenza, Singal, Amit G., Sharma, Rohini, Cortellini, Alessio, Gaillard, Vincent E., Chon, Hong Jae, Pinato, David J., Ang, Celina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9737420/
https://www.ncbi.nlm.nih.gov/pubmed/36497316
http://dx.doi.org/10.3390/cancers14235834

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9737420/
https://www.ncbi.nlm.nih.gov/pubmed/36497316
http://dx.doi.org/10.3390/cancers14235834

Ejemplares similares